In today’s session Novartis AG (ADR) (NVS) recorded an unusually high (654) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the January, 2017 put, expecting serious NVS decrease. With 654 contracts traded and 2154 open interest for the Jan, 17 contract, it seems this is a quite bearish bet. The option with symbol: NVS170120P00067500 closed last at: $1.3 or 18.8% down. About 328,175 shares traded hands. Novartis AG (ADR) (NYSE:NVS) has declined 10.16% since April 26, 2016 and is downtrending. It has underperformed by 15.42% the S&P500.
Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on January, 25. They expect $1.08 EPS, down 2.70% or $0.03 from last year’s $1.11 per share. NVS’s profit will be $2.83B for 16.02 P/E if the $1.08 EPS becomes a reality. After $1.23 actual EPS reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts -12.20% negative EPS growth.
Novartis AG (ADR) (NYSE:NVS) Ratings Coverage
Out of 9 analysts covering Novartis Ag (NYSE:NVS), 3 rate it a “Buy”, 2 “Sell”, while 4 “Hold”. This means 33% are positive. $110 is the highest target while $85 is the lowest. The $92.75 average target is 34.05% above today’s ($69.19) stock price. Novartis Ag has been the topic of 14 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Citigroup downgraded the stock to “Neutral” rating in Tuesday, March 29 report. Chardan Capital Markets initiated the stock with “Buy” rating in Tuesday, September 20 report. The stock of Novartis AG (ADR) (NYSE:NVS) earned “Buy” rating by Argus Research on Thursday, November 10. The rating was downgraded by Leerink Swann to “Market Perform” on Wednesday, March 23. The stock has “Buy” rating given by Chardan Capital Markets on Monday, October 10. Mainfirst downgraded the stock to “Underperform” rating in Wednesday, October 28 report. As per Tuesday, April 12, the company rating was downgraded by Morgan Stanley. Argus Research initiated Novartis AG (ADR) (NYSE:NVS) on Tuesday, April 5 with “Hold” rating. UBS downgraded the stock to “Neutral” rating in Friday, April 1 report.
According to Zacks Investment Research, “Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.”
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The company has a market cap of $181.04 billion. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. It has a 24.43 P/E ratio. The Company’s divisions include Pharmaceuticals, Alcon and Sandoz.
NVS Company Profile
Novartis AG, incorporated on March 1, 1996, is a holding company. The Firm specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. The Company’s portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s divisions include Pharmaceuticals, which researches, develops, makes, distributes and sells prescription medicines in the therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience and established medicines; Alcon, which operates through over three franchises: Surgical, Ophthalmic Pharmaceuticals and Vision Care, and Sandoz, which develops, makes and markets generic pharmaceutical products, follow-on biopharmaceutical products known as biosimilars, and other drug substances.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.